Drug Approval | June 14, 2024
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Accelerating sustainability in Indian pharma industry
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress
Innovative technologies and comprehensive services to strengthen Syntegon’s strategic growth
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
Subscribe To Our Newsletter & Stay Updated
